Mark Flather News Today

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Thursday, August 10, 2023. I would now like to turn the conference over to Mark […]

Operator: Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode.

Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipelinePH94B Phase 3 program for social anxiety disorder advancing towards important next stepsPH10 Phase 1 study initiated to facilitate plans for Phase 2B develo...

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipelineSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals livin...

Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 beginsPreliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD)SOUTH...

Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to...

Share: SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, ca...

Published: Jan 28, 2021 SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients. Preliminary data from that study shows that Tempol decreases cytokines from stimulated cells from COVID-19 patients. The collaboration expects to submit the final data to a peer re...